Ath Ethyl (Z)-2-(Aminothiazole-4-Yl)-2-Hydroxyimino Acetate

For the industrial synthesis of third- and fourth-generation cephalosporin antibiotics, ethyl (Z)-2-(aminothiazol-4-yl)-2-hydroxyimino acetate serves as the non-methylated oxime ester precursor that undergoes controlled O-alkylation to yield the corresponding methoxyimino, carboxymethoxyimino, or alkoxyimino side-chain intermediates. Production-scale plants handling this compound at throughputs exceeding 500 kg per batch typically receive the crystalline free base or its hydrochloride salt, pre-dried to a moisture content of ≤0.3 wt% (Karl Fischer titration) under vacuum at 40–45 °C for 8 h, to prevent hydrolysis of the ethyl ester moiety during subsequent N-acylation reactions. The material exhibits a Z/E isomer ratio of >99.5:0.5 as confirmed by HPLC on a C18 column with UV detection at 254 nm; deviation outside this specification has been demonstrated in commercial manufacturing campaigns to raise the diastereomeric impurity load in the final cephalosporin to >0.10%, triggering an out-of-specification result under Ph. Eur. monograph 01/2024:0998 (related substances test for ceftriaxone sodium). Regulatory filings in support of DMF Type II submissions for the downstream API routinely require a detailed description of the synthetic pathway originating from this ethyl hydroxyiminoacetate, including the derivatization step, process control of alkylating agent stoichiometry, and removal of N,O-dimethylhydroxylamine by-products when reductive methylation is employed.

Downstream handling in a cGMP intermediate workshop involves charging the powder into glass-lined reactors equipped with Hastelloy C-22 agitators and jacket temperature control capable of maintaining −15 °C during addition of ≥98% dimethyl sulfate. The alkylating reagent is metered to a molar ratio of 1.05–1.15 mol per mole of oxime substrate, while the pH is maintained at 8.5–9.2 by parallel dosing of 30% w/w sodium carbonate solution. Deviation from this alkalinity buffer has been documented in plant-scale incidents to accelerate O→N methyl transfer, forming the inert N-methylated thiazole isomer that does not participate in the subsequent active ester formation. After phase separation and vacuum distillation of the methylene chloride extract, the resulting ethyl (Z)-2-(aminothiazol-4-yl)-2-methoxyimino acetate is crystallized from isopropanol/water ( 3:1 v/v ) to yield a product with a melting point of 127–129 °C, which then enters the activated thioester preparation unit.

What Triggers the Shift from Hydroxyimino to Methoxyimino During Cefotaxime Sodium Manufacture?

In the commercial route to cefotaxime sodium sterile powder, the ethyl hydroxyiminoacetate intermediate is not directly condensed with 7-aminocephalosporanic acid (7-ACA). Instead, the hydroxyl group of the oxime must first be converted to methoxy, because the 2-methoxyimino pharmacophore confers the requisite stability against β-lactamase hydrolysis and improves the pharmacokinetic profile. The methylated side-chain acid is prepared via alkaline hydrolysis of the ethyl ester with 1.05 eq of sodium hydroxide in aqueous tetrahydrofuran at 20–25 °C, followed by acidification to precipitate (Z)-2-(aminothiazol-4-yl)-2-methoxyimino acetic acid. This free acid is then activated with 2-mercaptobenzothiazole and dicyclohexylcarbodiimide (DCC) in methylene chloride at 0–5 °C to form the corresponding benzothiazolyl thioester (MAEMBT). Condensation with 7-ACA is carried out at a molar ratio of 1.00:1.02 (side-chain active ester to 7-ACA) in anhydrous methylene chloride containing 2.5–3.0 equivalents of triethylamine; the mixture is held at −5 to 0 °C for 2 h, then warmed to 10 °C for phase transfer into the aqueous sodium bicarbonate extraction layer. Manufacturers operating under ICH Q7 guidelines for API GMP validate the hold time at this stage (≤90 min after reaction completion) to limit Δ2-cefotaxime isomer formation to <0.2%, as determined by a validated HPLC procedure using a LiChrospher 100 RP-18 column and phosphate buffer/acetonitrile mobile phase. Cefotaxime sodium final substance specifications mandate compliance with USP-NF 2023 monograph, including specific optical rotation between +58° and +64° (anhydrous basis), water content ≤3.0% (Karl Fischer), and pH 4.5–7.0 in aqueous solution.

Stringent control of residual methanol and methylene chloride is exerted because these solvents arise from the methoxyimino intermediate synthesis and the thioester coupling step, respectively. Validated cleaning procedures for multi-product stainless-steel ( 316L ) centrifuges used for cefotaxime sodium isolation mandate a rinse with purified water at 80 °C followed by a methanol flush, with swab limit verification against ICH Q3C Option 2 permitted daily exposures. Batches failing the clarity of solution test ( Ph. Eur. 2.2.1 ) have been traced in retrospective deviation reports to incomplete removal of the dicyclohexylurea by-product generated during active ester preparation; inline filtration through a 0.45 µm polypropylene cartridge immediately prior to spray drying and ethylene oxide sterilization of the dried powder is therefore an established corrective action.

When 7-Amino-3-[(1-Carboxy-1-methylethoxyimino)methyl]-3-cephem-4-carboxylic Acid (7-ACCA) Undergoes Enzymatic Resolution

In the production of ceftazidime pentahydrate, the ethyl hydroxyiminoacetate starting material enters a different derivatization pathway that introduces a quaternary carbon-bearing carboxyisopropoxy group on the oxime oxygen. The ethyl ester is first solubilized in dimethylformamide ( DMF ) at 25 °C, and anhydrous potassium carbonate ( 1.2 eq ) is suspended before the dropwise addition of tert-butyl 2-bromoisobutyrate ( 1.10–1.20 eq ) over 60 min. The alkylation proceeds at 35–40 °C for 8–10 h, with the reaction endpoint monitored by TLC (silica gel 60 F254, hexane/ethyl acetate 1:1, R_f of product 0.45). After aqueous work-up and vacuum distillation of DMF at <10 mbar and 50 °C bath temperature, the resulting tert-butyl-protected ester is hydrolyzed with formic acid to unmask the carboxylic function, yielding the side-chain free acid. Coupling with 7-aminocephalosporanic acid-tert-butyl ester then produces the protected ceftazidime intermediate, which undergoes global deprotection with trifluoroacetic acid/anisole ( 9:1 v/v ) at 0–5 °C. This step demands extreme moisture exclusion: Karl Fischer titration of the reaction mixture prior to TFA addition must indicate <500 ppm water to suppress the formation of the corresponding lactone degradation product that co-elutes with ceftazidime in the official USP HPLC system suitability test.

The inherent complexity of introducing a sterically congested gem-dimethyl group onto the oxime ether necessitates a precisely controlled agitation regime during the alkylation stage. Industrial-scale batches of 200–300 kg input ethyl hydroxyiminoacetate are processed in 1,000 L glass-lined reactors fitted with a retreat curve impeller; tip speed is limited to 1.8 m/s to minimize shear-induced emulsion formation with the aqueous potassium carbonate phase. Deviations in agitator speed of ±15% from the qualified parameter have been associated with a widened particle size distribution of the potassium bromide by-product, leading to variable filtration flux rates and a 2–4% drop in isolated yield after crystallisation from ethyl acetate/cyclohexane. Ceftazidime final substance tested according to Ph. Eur. monograph 01/2024:1405 must exhibit a pyrogen-free status confirmed by the Limulus amoebocyte lysate test at <0.10 EU/mg and absence of N,N-dimethylaniline (≤2 ppm by GC headspace), a requirement that directly drives the specification of the starting ethyl hydroxyiminoacetate for non-detectable aryl amine contamination.

Cefepime Dihydrochloride Monohydrate: Low-Temperature Acylation Kinetics and Side-Chain Resolution

Ethyl (Z)-2-(aminothiazol-4-yl)-2-hydroxyimino acetate destined for cefepime manufacture is first O-methylated under the same general protocol as described for cefotaxime, but the subsequent coupling chemistry diverges at the choice of the 7-aminocephem nucleus. The methylated side-chain acid is activated as the 1-hydroxybenzotriazole (HOBt) active ester using DCC in DMF at −10 °C, then added to a pre-cooled solution of 7-amino-3-[(1-methylpyrrolidinium)methyl]-3-cephem-4-carboxylate (7-ACP) hydrochloride. The acylation is conducted in a two-phase system of water and dichloromethane at pH 7.5–8.0 (maintained with 10% aqueous sodium carbonate) and a temperature envelope of −15 to −10 °C. At this temperature threshold, the pseudo-first-order rate constant for the desired N-acylation is approximately 3–5 times higher than that of competitive hydrolysis of the HOBt ester, a critical kinetic selectivity that permits 90–92% theoretical yield on the 7-ACP basis. Process analytical technology (PAT) inline ReactIR probes monitoring the disappearance of the HOBt ester carbonyl stretch at 1815 cm⁻¹ trigger the endpoint decision within 30–45 min, after which the product is isolated as the dihydrochloride monohydrate by pH adjustment to 1.0–1.5 with concentrated hydrochloric acid, followed by precipitation with acetone.

The residual solvent profile of cefepime bulk drug substance must comply with ICH Q3C limits for Class 2 solvents: dichloromethane ≤600 ppm, DMF ≤880 ppm, and acetone ≤5,000 ppm. Manufacturing facilities employing tray dryers at 40 °C under a nitrogen sweep of 0.5 m/s velocity report achieving these thresholds after 16 h drying, provided the wet cake granulometry is D₉₀ < 150 µm. Granules larger than this cutoff have repeatedly shown dichloromethane retention above the limit, requiring a secondary drying step. The finished product is assayed against USP-NF 2023 Cefepime Hydrochloride monograph, with particular attention to the E-isomer content (≤0.8%) originating from incomplete retention of the Z-configuration during the methylation of the starting ethyl hydroxyiminoacetate.

A formulation-critical aspect of cefepime for injection is the reconstituted solution’s compatibility with common intravenous diluents. Batches of ethyl hydroxyiminoacetate that contain trace thiazole-related process impurities at levels exceeding 0.05 area% by HPLC (at 270 nm) have been correlated with a slight haze observed after reconstitution of the freeze-dried cefepime hydrochloride with 0.9% sodium chloride injection USP. This necessitated the introduction of a tangential-flow ultrafiltration step ( 10 kDa MWCO polyethersulfone membrane) post-synthesis, which adds 3–4% processing cost but eliminates the turbidity risk.

Cefpodoxime Proxetil: Enteric Ester Coupling and In Situ Side-Chain Activation

For the orally absorbed prodrug cefpodoxime proxetil, the side-chain methoxyiminoacetic acid derived from ethyl hydroxyiminoacetate is condensed with 7-amino-3-methoxymethyl-3-cephem-4-carboxylic acid (7-AMCA) prior to esterification of the 4-position carboxylic acid with 1-iodoethyl isopropyl carbonate. The coupling uses the same active thioester strategy as cefotaxime, but with process adjustments to accommodate the 7-AMCA nucleus, which is less soluble in chlorinated solvents. A mixed solvent system of tetrahydrofuran and water ( 3:1 v/v ) containing 5% w/w sodium bicarbonate is employed, and the reaction temperature is kept at 10–15 °C to avoid precipitation of the sodium salt of the intermediate. Side-chain active ester to 7-AMCA molar ratio is set at 1.15:1.00 to compensate for the aqueous hydrolysis loss; completion is verified by TLC after 3 h. After coupling, the free acid is isolated and then esterified with 1-iodoethyl isopropyl carbonate in DMF using potassium carbonate as base. The resulting cefpodoxime proxetil is a diastereomeric mixture at the ester carbon; the USP monograph specifies a diastereomer ratio of 1:1 within a tolerance of ±5% by HPLC.

Residual heavy metals control originates upstream: the palladium on carbon catalyst used in the hydrogenolysis of the cephalosporin nucleus must be thoroughly scavenged, but an additional risk vector is the potential for nickel contamination from the stainless-steel reactor during methylation of the hydroxyiminoacetate under alkaline conditions. Contract manufacturing organisations supplying cefpodoxime proxetil intermediates routinely screen the methoxyimino ethyl ester for nickel ( <5 ppm by ICP-MS) and chromium ( <10 ppm ) as part of the raw material release specification per ICH Q3D Guideline for Elemental Impurities. Failure to comply has led to lot rejections when the final dosage form exceeds the parenteral limit for nickel ( 5.0 µg/day ), even though the oral route has a higher permitted daily exposure, because the testing protocol applies the stricter parenteral criterion as a conservative safety measure.

Cefixime Trihydrate: Enantiomeric Purity Control at the Side-Chain Activation Stage

The synthesis of cefixime [6R-[6α,7β(Z)]]-7-[[(2-amino-4-thiazolyl)(carboxymethoxy)imino]acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid — requires that the ethyl hydroxyiminoacetate be O-alkylated with ethyl bromoacetate instead of dimethyl sulfate. This introduces a carboxymethyl ether on the oxime, which must later be deprotected to the free carboxymethoxy side chain. The carboxymethylation is performed in anhydrous acetonitrile with 2.5 eq of finely ground potassium carbonate and a catalytic amount of potassium iodide ( 0.05 eq ) at a reflux temperature of 81–82 °C for 6 h. Exothermic excursion above 85 °C during the initial addition of ethyl bromoacetate triggers a side reaction forming the thiazole N-alkylation product, which is inseparable from the desired O-alkyl oxime by simple crystallisation. The resulting disubstituted impurity has been identified by ¹H NMR (signal at δ 4.62 ppm for the N–CH₂COOEt moiety) and its content is limited to ≤0.15 area% in the in-process control sample drawn at 3 h. Effective control is achieved by stepwise addition of the alkylating agent over 90 min under vigorous agitation (Reynolds number >10,000 in the 500 L reactor).

Following chromatographic purification on silica gel, the protected diester is selectively hydrolysed with 1.0 N sodium hydroxide in ethanol/water at 10 °C to cleave the ethyl ester of the side chain while preserving the carboxymethyl ethyl ester. The monoacid then reacts with 7-amino-3-vinyl-3-cephem-4-carboxylic acid (7-AVCA) using the mixed anhydride method with pivaloyl chloride and N-methylmorpholine at −20 °C. The coupling product, after full deprotection with aluminium trichloride in nitromethane/anisole, yields cefixime trihydrate. The official Ph. Eur. monograph for cefixime (01/2024:1188) lists the specific optical rotation at −71° to −79° (anhydrous substance, c = 1 in methanol), a parameter highly sensitive to the enantiomeric integrity of the side chain. Any racemisation of the chiral centre of the 7-AVCA nucleus during coupling, or use of ethyl hydroxyiminoacetate with E-isomer content above 0.3%, is directly reflected in a lowered absolute rotation value and batch failure.

A secondary application that does not involve cephalosporin frameworks but exploits the aminothiazole ring is the preparation of sulfathiazole derivatives for specialized veterinary formulations. In this niche, the ethyl hydroxyiminoacetate is hydrolysed to the free acid and decarboxylated under acidic conditions to yield 2-aminothiazole, which subsequently undergoes N-acetylation and condensation with sulfanilamide. However, the yield of this sequence from the ethyl ester is less than 65%, and the process competes with a more economical direct synthesis of 2-aminothiazole from thiourea and chloroacetaldehyde. Consequently, this route is practised only when existing stocks of the hydroxyiminoacetate are available as a by-product from a cephalosporin campaign, making it a batch-dependent auxiliary process rather than a stand-alone commercial pathway.

Across all described cephalosporin routes, the pre-drying requirement for ethyl (Z)-2-(aminothiazol-4-yl)-2-hydroxyimino acetate is non-negotiable when ambient relative humidity exceeds 60%. Material exposed to moisture for extended periods undergoes partial hydrolysis to the free acid, which cross-links during the alkylation step and forms oligomeric by-products detectable by size-exclusion chromatography. Furthermore, combining this intermediate with amine-based additives such as triethylamine or imidazole in a melt or highly concentrated solution without strict temperature control below 0 °C initiates an exothermic N-acyl migration that results in an inactive 4-aminothiazole regioisomer. These operational boundaries have been codified in the internal technology transfer documents of several API manufacturers holding approval from the EDQM for their cephalosporin CEP dossiers.